Please login to the form below

Not currently logged in
Email:
Password:

ofatumumab

This page shows the latest ofatumumab news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

The verdict is based on data from the RESONATE trials and a three-year follow-up study, one of which showed that in comparison with GlaxoSmithKline's Arzerra (ofatumumab), the BTK

Latest news

  • Novartis drug works in secondary progressive MS Novartis drug works in secondary progressive MS

    The drug is facing patent expiry in 2019, however, so with siponimod Novartis has a means of extending its franchise - which also includes recently-acquired CD20-targeteing drug Arzerra (ofatumumab) - once

  • Novartis says Cosentyx is 'outpacing competitors' Novartis says Cosentyx is 'outpacing competitors'

    Particular attention is given in its presentations to two new candidates - multiple sclerosis candidate OMB157 (ofatumumab) and QAW039 (fevipiprant) for asthma.

  • Novartis buys rights to GSK's Arzerra in MS for $1bn Novartis buys rights to GSK's Arzerra in MS for $1bn

    GlaxoSmithKline has sold rights to use its ofatumumab antibody in autoimmune diseases to Novartis in a $1bn agreement. ... Novartis will pay $300m upfront to Glaxo for ofatumumab, followed by another $200m after the start of late-stage clinical trials of

  • Imbruvica shines in combination trial Imbruvica shines in combination trial

    An earlier trial of the drug as a single-agent therapy in CLL indicated it was more effective than GlaxoSmithKline (GSK) and Genmab's Arzerra (ofatumumab).

  • England's Cancer Drugs Fund: Fixing a broken system England's Cancer Drugs Fund: Fixing a broken system

    GlaxoSmithKline has been the hardest hit in terms of drugs, given that three of its treatments: breast cancer medicine Tyverb (lapatinib), leukaemia drug Arzerra (ofatumumab) and non-adipocytic soft tissue sarcoma ... GlaxoSmithKline's Tyverb (lapatinib):

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Option to acquire. 1250. GSK. Novartis. Arzerra [ofatumumab] anti CD20 monoclonal antibody in oncology indications.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics